Amphastar Pharmaceuticals
AMPH
133 hedge funds and large institutions have $471M invested in Amphastar Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 58 increasing their positions, 42 reducing their positions, and 16 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 42
3% more capital invested
Capital invested by funds: $459M → $471M (+$12.5M)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
0.56% less ownership
Funds ownership: 47.99% → 47.43% (-0.56%)
1% less funds holding
Funds holding: 135 → 133 (-2)
96% less call options, than puts
Call options by funds: $21K | Put options by funds: $517K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$12M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.39M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.24M |
| 4 |
Renaissance Technologies
New York
|
+$3.06M |
| 5 |
MSL
Mackay Shields LLC
New York
|
+$2.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$12.3M |
| 2 |
Morgan Stanley
New York
|
-$4.57M |
| 3 |
Goldman Sachs
New York
|
-$3.33M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.23M |
| 5 |
SAM
Sawgrass Asset Management
Ponte Vedra Beach,
Florida
|
-$1.3M |
AMPH Hedge Fund Activity: Q2 2019 in Review
133 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q2 2019, worth a combined $471M — up 2.7% from $459M a quarter earlier.
Fund positioning in AMPH was balanced in Q2 2019: 16 funds opened new positions, 16 closed out, 58 added to existing stakes and 42 trimmed.
The largest buyer was Nuveen, opening a new position worth an estimated $12M. The largest seller was Invesco, cutting an estimated $12.3M.
- 133 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q2 2019, down from 135 in Q1 2019.
- Funds reported $471M of Amphastar Pharmaceuticals stock for Q2 2019, up 2.7% quarter-over-quarter.
- 16 funds opened new Amphastar Pharmaceuticals positions in Q2 2019 and 16 closed out, a net change of 0 holders.
- The largest Amphastar Pharmaceuticals buyer in Q2 2019 was Nuveen, an estimated $12M added.
- The largest Amphastar Pharmaceuticals seller in Q2 2019 was Invesco, an estimated $12.3M sold.
Based on aggregated 13F filings for Q2 2019.